{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:02:59Z","timestamp":1781067779510,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013103","name":"Shanghai General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.diabres.2025.112954","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T06:44:36Z","timestamp":1761288276000},"page":"112954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists\u2014A systematic review and Bayesian network meta-analysis"],"prefix":"10.1016","volume":"230","author":[{"given":"Ying","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guikai","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijiong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0466-3608","authenticated-orcid":false,"given":"Yaxing","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.112954_b0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: challenges, hopes, and anticipated successes","volume":"9","author":"Nauck","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0010","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11883-022-01041-7","article-title":"Glucagon-like peptide 1 receptor agonists: a medication for obesity management","volume":"24","author":"Taha","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2025.112954_b0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0020","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1021\/acs.molpharmaceut.9b00308","article-title":"Glucagon-like peptide-1 receptor agonists and strategies to improve their efficiency","volume":"16","author":"Alavi","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.diabres.2025.112954_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108904","article-title":"Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: a network meta-analysis","volume":"177","author":"Xia","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2025.112954_b0030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7326\/M15-1432","article-title":"Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis","volume":"164","author":"Zaccardi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2025.112954_b0035","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112954_b0040","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)","volume":"38","author":"Giorgino","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112954_b0045","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","article-title":"Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study","volume":"385","author":"Blonde","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112954_b0050","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0055","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1111\/dom.13340","article-title":"Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial","volume":"20","author":"Chen","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0060","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/dom.13506","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and\/or a sulphonylurea: a 52-week open-label, randomized phase III trial","volume":"21","author":"Wang","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0065","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/dom.12540","article-title":"Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and\/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study","volume":"17","author":"Araki","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0070","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/dom.12634","article-title":"A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)","volume":"18","author":"Dungan","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0343","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112954_b0075","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.12937","article-title":"Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)","volume":"19","author":"Pozzilli","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0080","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/dom.12479","article-title":"Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2\u2009years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study","volume":"17","author":"Weinstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0085","doi-asserted-by":"crossref","unstructured":"Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, et al. Erratum. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014;37:2159-2167. Diabetes Care 2015;38:1393\u20134. Doi: 10.2337\/dc15-er07b.","DOI":"10.2337\/dc15-er07b"},{"key":"10.1016\/j.diabres.2025.112954_b0090","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1111\/dom.13764","article-title":"Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin","volume":"21","author":"Frias","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0095","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/dom.12534","article-title":"Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study","volume":"17","author":"Miyagawa","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0100","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.2337\/dc12-1333","article-title":"Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas","volume":"36","author":"Davies","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112954_b0105","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112954_b0110","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0115","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2337\/dc18-0680","volume":"41","author":"Jabbour","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112954_b0120","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.2337\/dc19-1350","article-title":"Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial","volume":"43","author":"Jabbour","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112954_b0125","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112954_b0130","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(14)70029-4","article-title":"Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial","volume":"2","author":"Diamant","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0135","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112954_b0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112954_b0145","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.clinthera.2012.07.007","volume":"34","author":"Inagaki","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabres.2025.112954_b0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.2040-1124.2012.00238.x","article-title":"Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus","volume":"4","author":"Ji","year":"2013","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2025.112954_b0155","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/dom.12908","article-title":"Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study","volume":"19","author":"Gadde","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0160","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/dom.13056","article-title":"Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes","volume":"20","author":"Wysham","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0165","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/dom.13266","article-title":"Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study","volume":"20","author":"Guja","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0180","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0185","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0190","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0195","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0200","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/dom.14232","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial","volume":"23","author":"Ji","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0205","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0210","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/dom.13082","article-title":"Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes","volume":"20","author":"Seino","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0215","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0220","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/dom.13218","article-title":"Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial","volume":"20","author":"Kaku","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0225","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/1753-0407.12397","article-title":"Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients","volume":"9","author":"Chen","year":"2017","journal-title":"J Diabetes"},{"key":"10.1016\/j.diabres.2025.112954_b0230","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/dom.14198","article-title":"Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: a multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial","volume":"23","author":"Shuai","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0235","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/dom.14163","article-title":"Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: a multicentre, randomized, double-blind, placebo-controlled, phase 3b trial","volume":"22","author":"Gao","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112954_b0240","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0245","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112954_b0250","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112954_b0255","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112954_b0260","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112954_b0265","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.112954_b0270","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","article-title":"Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0275","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0280","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2025.112954_b0285","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin Lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2025.112954_b0290","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.112954_b0295","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","article-title":"Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial","volume":"29","author":"Gao","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.diabres.2025.112954_b0300","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-018-0703-2","article-title":"Diabetes, cardiovascular disease and the microcirculation","volume":"17","author":"Strain","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2025.112954_b0305","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review","volume":"5","author":"Honigberg","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabres.2025.112954_b0310","doi-asserted-by":"crossref","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Erratum. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67. Diabetes Care 2023;46:1722. Doi: 10.2337\/dc23-er09a.","DOI":"10.2337\/dc23-er09a"},{"key":"10.1016\/j.diabres.2025.112954_b0315","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41574-020-0381-5","article-title":"Diet and exercise in the prevention and treatment of type 2 diabetes mellitus","volume":"16","author":"Magkos","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabres.2025.112954_b0320","first-page":"206","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinol (Torino)"},{"key":"10.1016\/j.diabres.2025.112954_b0325","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1055\/a-2148-6321","article-title":"Implications of ozempic and other semaglutide medications for facial plastic surgeons","volume":"39","author":"Humphrey","year":"2023","journal-title":"Facial Plast Surg"},{"key":"10.1016\/j.diabres.2025.112954_b0330","doi-asserted-by":"crossref","first-page":"NP809","DOI":"10.1093\/asj\/sjae132","article-title":"Decoding the implications of glucagon-like peptide-1 receptor agonists on accelerated facial and skin aging","volume":"44","author":"Ridha","year":"2024","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.diabres.2025.112954_b0335","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.diabres.2025.112954_b0340","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:54:17Z","timestamp":1781067257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725009684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":69,"alternative-id":["S0168822725009684"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112954","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists\u2014A systematic review and Bayesian network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112954"}}